Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy.

Tulsyan S, Agarwal G, Lal P, Mittal B.

Clin Chim Acta. 2014 Jul 1;434:21-8. doi: 10.1016/j.cca.2014.04.009. Epub 2014 Apr 24.

PMID:
24768782
2.

Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach.

Tulsyan S, Chaturvedi P, Singh AK, Agarwal G, Lal P, Agrawal S, Mittal RD, Mittal B.

Gene. 2014 Jun 10;543(1):69-75. doi: 10.1016/j.gene.2014.04.004. Epub 2014 Apr 2.

PMID:
24704000
3.

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV.

Br J Cancer. 2010 Mar 16;102(6):1003-9. doi: 10.1038/sj.bjc.6605587. Epub 2010 Feb 23.

4.

Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.

Seredina TA, Goreva OB, Talaban VO, Grishanova AY, Lyakhovich VV.

BMC Med Genet. 2012 Jun 15;13:45.

5.

Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.

Nakajima M, Komagata S, Fujiki Y, Kanada Y, Ebi H, Itoh K, Mukai H, Yokoi T, Minami H.

Pharmacogenet Genomics. 2007 Jun;17(6):431-45.

PMID:
17502835
6.
7.

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.

Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD.

Pharmacogenet Genomics. 2008 Jun;18(6):515-23. doi: 10.1097/FPC.0b013e3282fc9766.

PMID:
18496131
8.

Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.

Haroun F, Al-Shaar L, Habib RH, El-Saghir N, Tfayli A, Bazarbachi A, Salem Z, Shamseddine A, Taher A, Cascorbi I, Zgheib NK.

Cancer Chemother Pharmacol. 2015 Jan;75(1):207-14. doi: 10.1007/s00280-014-2632-4. Epub 2014 Nov 27.

PMID:
25428516
9.

Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.

Afsar NA, Ufer M, Haenisch S, Remmler C, Mateen A, Usman A, Ahmed KZ, Ahmad HR, Cascorbi I.

Eur J Clin Pharmacol. 2012 Apr;68(4):389-95. doi: 10.1007/s00228-011-1134-0. Epub 2011 Oct 20.

PMID:
22012257
10.

Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma.

Shu W, Chen L, Hu X, Zhang M, Chen W, Ma L, Liu X, Huang J, Pang T, Li J, Zhang Y.

J Clin Pharmacol. 2017 Jul;57(7):886-898. doi: 10.1002/jcph.878. Epub 2017 Feb 9.

PMID:
28181240
11.

Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.

Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, Flockhart DA, Illei GG.

Arthritis Rheum. 2004 Jul;50(7):2202-10.

12.

Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.

Low SK, Kiyotani K, Mushiroda T, Daigo Y, Nakamura Y, Zembutsu H.

J Hum Genet. 2009 Oct;54(10):564-71. doi: 10.1038/jhg.2009.79. Epub 2009 Aug 21.

PMID:
19696793
13.
14.

Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

van Schaik RH.

Invest New Drugs. 2005 Dec;23(6):513-22. Review.

PMID:
16267627
15.

[Expression of cytochrome P450 enzymes in human nasopharyngeal carcinoma and non-cancerous nasopharynx tissue].

Jiang JH, Jia WH, Qin HD, Liang H, Pan ZG, Zeng YX.

Ai Zheng. 2004 Jun;23(6):672-7. Chinese.

PMID:
15191668
16.

Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer.

Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, McLeod HL, Synold TW.

Pharmacogenomics J. 2007 Oct;7(5):362-5. Epub 2007 Jan 16.

PMID:
17224914
17.

A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis.

Modugno F, Knoll C, Kanbour-Shakir A, Romkes M.

Breast Cancer Res Treat. 2003 Dec;82(3):191-7.

PMID:
14703066
18.
19.

Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.

Singh MS, Francis PA, Michael M.

Breast. 2011 Apr;20(2):111-8. doi: 10.1016/j.breast.2010.11.003. Epub 2010 Dec 24. Review.

PMID:
21185724
20.

Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.

Su HI, Sammel MD, Velders L, Horn M, Stankiewicz C, Matro J, Gracia CR, Green J, DeMichele A.

Fertil Steril. 2010 Jul;94(2):645-54. doi: 10.1016/j.fertnstert.2009.03.034. Epub 2009 Apr 18.

Supplemental Content

Support Center